Reinventing Patent Quality: A NIST-Based Program for the USPTO 

The United States Patent and Trademark Office (USPTO) is the cornerstone of America’s innovation engine, issuing patents that fuel technological advancement and economic growth. However, perceptions of poor patent quality, driven by vague claim language, inconsistent examinations, costly litigation, and occasional bad rulings by the Court of Appeals for the Federal Circuit (CAFC) or the […]

Time to Turn the US Rejection Office Back into the US Patent Office – Part 2

Analyzing the US Rejection Office Given the USPTO’s pro-rejection tendencies introduced in Part 1 of this series, one might expect the agency would function like a well-oiled machine to properly reject claims in a smooth and efficient fashion. MPEP guidance on how to examine and reject claims is extensive, straightforward and reasonable. Examples include: MPEP […]

Time to Turn the US Rejection Office Back into the US Patent Office – Part 1

In 2024, the Sunwater Institute’s study Patent Quality in the United States, Findings and Suggestions for Policy Makers, determined that  This outcome was observed in groups that examined chemical, mechanical, telecommunications, computer and electronical technologies. From the Sunwater Institute report, it can be estimated that TC3600 improperly rejects 15% of claims directed to electric vehicles, […]

Vishal Amin and the USPTO: A Threat to American Innovation

I first met Vishal Amin in October 2013. He was Representative Lamar Smith’s senior lawyer on the House Judiciary Committee driving the Innovation Act to passage. My company had just lost its investors due to the Leahy-Smith America Invents Act’s (AIA) creation of the Patent Trial and Appeal Board (PTAB). Back then, the PTAB was […]

Dear Congress, the PTAB Hinders Innovation and Threatens National Security

The Patent Trial and Appeal Board (PTAB) effectively invalidates 84% of the patents it fully adjudicates. That fact comes directly from the U.S. Patent and Trademark Office’s (USPTO) PTAB Trial Statistics FY23 End of Year Outcome. This astronomical PTAB invalidation rate has effectively shut down investment in early-stage startups, particularly in vital sectors that require […]